Heron Therapeutics (HRTX) Misses Q3 EPS by 9c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.10), $0.09 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $38.2 million versus the consensus estimate of $39.49 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Yen Jumps More Than 1% To Trade At 158.22 Per Us Dollar
• Advent International proposes $1.02-per-share buyout of Definitive Healthcare
• EXL president Vivek Jetley to depart for Hexaware CEO role